FASN Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant FASN.
|Application ||WB, IHC, IF, IP|
|Calculated MW||273427 Da|
|Other Names||Fatty acid synthase, [Acyl-carrier-protein] S-acetyltransferase, [Acyl-carrier-protein] S-malonyltransferase, 3-oxoacyl-[acyl-carrier-protein] synthase, 3-oxoacyl-[acyl-carrier-protein] reductase, 3-hydroxyacyl-[acyl-carrier-protein] dehydratase, Enoyl-[acyl-carrier-protein] reductase, Oleoyl-[acyl-carrier-protein] hydrolase, FASN, FAS|
|Target/Specificity||FASN (AAH07909, 1 a.a. ~ 439 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||FASN Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The enzyme encoded by this gene is a multifunctional protein. Its main function is to catalyze the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids. In some cancer cell lines, this protein has been found to be fused with estrogen receptor-alpha (ER-alpha), in which the N-terminus of FAS is fused in-frame with the C-terminus of ER-alpha.
1.Old proteins - new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells.Gorr TA, Wichmann D, Pilarsky C, Theurillat JP, Fabrizius A, Laufs T, Bauer T, Koslowski M, Horn S, Burmester T, Hankeln T, Kristiansen G.Acta Physiol (Oxf). 2011 Jul;202(3):563-581.2.Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.Kristiansen G, Rose M, Geisler C, Fritzsche FR, Gerhardt J, Luke C, Ladhoff AM, Knuchel R, Dietel M, Moch H, Varga Z, Theurillat JP, Gorr TA, Dahl E.Br J Cancer. 2010 Jun 8;102(12):1736-45.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.